Company Profile
Profil emiten IDX — keuangan, direksi, komisaris, anak usaha
Merck Tbk
MERK
Sector: Healthcare
Industry: Pharmaceuticals
Sub Sector: Pharmaceuticals & Health Care Research
Sub Industry: Pharmaceuticals
Live quote
tidak tersedia
Highlight Keuangan (2026 Q2) (In Rp)
EPS
499
ROE
23,18%
ROA
18,21%
Book Value
2.152
Net Income
111,78 M
Total Sales
630,24 M
Total Assets
1,23 T
DER
0.27x
Struktur Pemegang Saham (>1%)
Free Float Information
Saham tersebar di publik
7,50%
MERCK HOLDING GMBH 🔗
73,99%
· Lokal
EMEDIA EXPORT COMPANY MBH 🔗
12,66%
Firm · Asing
THERESIA SETYOWATI SUROSO 🔗
2,50%
Individual · Lokal
CITIBANK NEW YORK S/A RAINBOW FUND LP 🔗
2,16%
Partnership · Asing
CACEIS BANK/NON TREATY UCITS CLIENTS 🔗
1,19%
Bank · Asing
Tentang Perusahaan
PT Merck Tbk (the Company) is domiciled in Indonesia and located at Jl. TB Simatupang No. 8, Pasar Rebo, East Jakarta, was established in framework of Law No. 1 of 1967 and Law No. 11 of 1970 on foreign capital investment by deed of notary public Eliza Pondaag, SH dated 14 October 1970 No. 29. PT Merck Indonesia is a member of the Merck International Group. The company produces pharmaceutical products with production facility in East Jakarta. It commenced its operation in 1974 in manufacturing medical products, such as Songobian and Neurobion.
Produk & Lini Bisnis
The Company engages in the pharmaceutical industry and trading.
Dewan Direksi
EY
Evie Yulin
President Director
BN
Bambang Nurcahyo
Director
AA
Arryo Aritrixso Wachjuwidajat.
Director
Dewan Komisaris
TM
Tang Mei Lin
President Commissioner
PS
Parulian Simanjuntak
Independent Commissioner
Anak Usaha & Afiliasi
NamaDomisili%
 %
Trend Keuangan (5 periode terakhir) — hover bar untuk detail
Total Sales Net Income (+) Net Income (-)
1,2M 901jt 600jt 300jt 0 Sales 2025Q2: Rp 480.156.882 Net Income 2025Q2: Rp 22.510.336 2025Q2 Sales 2025Q3: Rp 814.110.064 Net Income 2025Q3: Rp 102.099.345 2025Q3 Sales 2025Q4: Rp 1.200.666.779 Net Income 2025Q4: Rp 243.896.434 2025Q4 Sales 2026Q1: Rp 283.105.215 Net Income 2026Q1: Rp 65.179.144 2026Q1 Sales 2026Q2: Rp 630.236.488 Net Income 2026Q2: Rp 111.775.601 2026Q2
2025 Q2
EPS 100
ROE 5,43%
2025 Q3
EPS 304
ROE 16,34%
2025 Q4
EPS 544
ROE 25,00%
2026 Q1
EPS 582
ROE 25,05%
2026 Q2
EPS 499
ROE 23,18%
Laporan Keuangan Historis (5 Periode Terakhir) (In Rp)
PeriodeTotal SalesNet IncomeTotal AssetsTotal EquityEPSROEDER
2026 Q2 630,24 M 111,78 M 1,23 T 964,29 M 499 23,18% 0.27x
2026 Q1 283,11 M 65,18 M 1,32 T 1,04 T 582 25,05% 0.27x
2025 Q4 1,20 T 243,90 M 1,27 T 975,71 M 544 25,00% 0.30x
2025 Q3 814,11 M 102,10 M 987,93 M 833,21 M 304 16,34% 0.19x
2025 Q2 480,16 M 22,51 M 1,01 T 829,78 M 100 5,43% 0.21x
Trend Harga Penutupan & Book Value — hover titik untuk detail
Close Price Book Value
3,8K 3,3K 2,8K 2,3K 1,8K Book Value 2025Q2: Rp 1.852 Close 2025Q2: Rp 3.010 2025Q2 Book Value 2025Q3: Rp 1.860 Close 2025Q3: Rp 2.860 2025Q3 Book Value 2025Q4: Rp 2.178 Close 2025Q4: Rp 3.350 2025Q4 Book Value 2026Q1: Rp 2.323 Close 2026Q1: Rp 3.070 2026Q1 Book Value 2026Q2: Rp 2.152 Close 2026Q2: Rp 3.600 2026Q2
2025 Q2
Close 3.010
BV 1.852
ROA 4,47%
2025 Q3
Close 2.860
BV 1.860
ROA 13,78%
2025 Q4
Close 3.350
BV 2.178
ROA 19,17%
2026 Q1
Close 3.070
BV 2.323
ROA 19,69%
2026 Q2
Close 3.600
BV 2.152
ROA 18,21%
History Harga Penutupan & Book Value
TahunQrtClose Price (Rp)Book Value (Rp)ROA
2026 2 3.600 2.152 18,21%
2026 1 3.070 2.323 19,69%
2025 4 3.350 2.178 19,17%
2025 3 2.860 1.860 13,78%
2025 2 3.010 1.852 4,47%
Data diperbarui pada: 2026-05-12 11:15:54